• Français
OCPI
  • Otsuka Canada
  • About
    • About OCPI
    • Otsuka Culture
    • Otsuka History
  • Products
  • Community
    • Otsuka’s Involvement
    • Grants and Donations
  • Careers
    • Careers
    • Available Careers
  • Contact
Select Page

Health Canada Approves Otsuka and Lundbeck’s ABILIFY MAINTENA® (aripiprazole for prolonged release injectable suspension) Alternative Initiation Regimen

Search

Recent Posts

  • Otsuka Canada Pharmaceutical Inc. announces Health Canada approval of KORSUVA® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients
  • Otsuka Canada Pharmaceutical Inc. announces Health Canada approval of TAVNEOS® (avacopan) for ANCA-Associated Vasculitis
  • Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
  • Health Canada Approves Otsuka and Lundbeck’s ABILIFY MAINTENA® (aripiprazole for prolonged release injectable suspension) Alternative Initiation Regimen

Recent Comments

    Archives

    • August 2022
    • April 2022
    • September 2021
    • March 2021

    Categories

    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org